A Study to Evaluate the Efficacy and Safety of HSK3486 in the Induction of General Anesthesia
Status:
Recruiting
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, single-blind, propofol injectable emulsion
parallel-controlled Phase III clinical study. A total of patients undergoing elective surgery
are intended to be enrolled and randomly assigned to HSK3486 group and propofol group in a
2:1 ratio.
Phase:
Phase 3
Details
Lead Sponsor:
Haisco Pharmaceutical Group Co., Ltd. Sichuan Haisco Pharmaceutical Group Co., Ltd.